Hepatitis B Virus Destroyed by Inovio’s Vaccine
Inovio Therapeutic Hepatitis B Vaccine Killer T Cells Demonstrate Potential to Clear HBV in Liver
Inovio Advances New Disease Therapy, Where 400 Million Patients Lack Effective Treatment
By Inovio Pharmaceuticals, Inc.
Published: Monday, Nov. 12, 2012 – 1:10 am
BLUE BELL, Pa., Nov. 12, 2012 — /PRNewswire/ — Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that its synthetic hepatitis B (HBV) therapeutic vaccine generated strong T cell responses that eliminated targeted liver cells in mice. This data points to the DNA vaccine’s potential to clear HBV infection and thereby prevent liver cancer in humans, an encouraging development given that nearly one-third of the world’s population is infected with hepatitis B, with 400 million at risk of developing liver cancer.
Results from this preclinical study appear in the peer-reviewed journal, Cancer Gene Therapy, in an article entitled, “Synthetic DNA immunogen encoding hepatitis B core antigen drives immune response in liver.”
Continue reading this entire article:
Abbott's Hep C Drug Trio Cures Most in a Few Months
BIT225 in Phase II Trial for HIV and Hep C Co-Infection